FDA Issues Counterfeit Avastin Alert
February 14, 2012
The US Food and Drug Administration (FDA) has issued an alert that counterfeit Avastin—a drug approved for cancer treatment that is often used off-label to treat wet macular degeneration—has gotten into the US marketplace. More detailed information, including suspect counterfeit lot numbers, is available on the website of the drug's manufacturer Genentech.
Interested people can visit the site, which includes background on the situation and photos of the bottle and packaging of both the real and the counterfeit drugs.
Those who are getting injections of Avastin, or caring for people who are, may want to discuss this matter with their doctors. The FDA is expected to provide additional information on this situation.
View all news updates for macular degeneration
Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.